Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo

NCT07690501 | Completed

• 1 other identifier: 36264MD92/5/23
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.

Conditions

Adipose-derived Stem Cells; Excimer Light; Stable Vitiligo

Outcome Measures

Primary Outcomes (1)

• Vitiligo Disease Activity (VIDA) Score

  The Vitiligo Disease Activity (VIDA) Score is a 6-point clinical scale used to measure the progression or stability of vitiligo. The scale ranges from -1 to +4, where higher numbers indicate more recent and rapid disease activity: * 4: Active disease (new lesions or expansion) within the last 6 weeks. * 3: Active disease between 6 weeks and 3 months. * 2: Active disease between 3 and 6 months. * 1: Active disease between 6 and 12 months. 0: Stable disease with no changes for 1 year or longer. * 1: Stable for 1 year or longer, showing signs of spontaneous repigmentation

  6 months post-procedure

Study Arms (1)

Study group

EXPERIMENTAL

Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least

Procedure: Adipose-derived Stem Cells Combined With Excimer Light

Interventions

Adipose-derived Stem Cells Combined With Excimer Light PROCEDURE

All patients received adipose-derived stem cells combined with excimer light.

Study group

Eligibility Criteria

• Age: 15 Years - 52 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least.
• Patients who will accept to be enrolled in the study and will sign an informed consent.

You may not qualify if:

• Unstable vitiligo for more than 6 months.
• Current bacterial or viral infection in the treatment area.
• Patients with unrealistic expectation.
• Very thin patients "poor donor areas".
• Patients with uncontrolled systemic disease such as diabetes or hypertension.
• Patients with hepatitis B or C virus infection.
• Patients with any other skin disease.
• Patients with bleeding or coagulopathy disorders.
• Pregnancy and lactation.
• Patients who received topical treatment for vitiligo during the last month, or systemic treatment during the past three months before the study.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer of Dermatology and Venereology, Faculty of Medicine, Tanta University, Egypt

Study Record Dates

• First Submitted: July 1, 2026
• First Posted: July 8, 2026
• Study Start: August 1, 2023
• Primary Completion: September 1, 2025
• Study Completion: September 1, 2025
• Last Updated: July 8, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)